Prognostic value of alkaline phosphatase and gamma-glutamyl transferase in patients with metastatic pancreatic cancer.
Martina CatalanoGiandomenico RovielloGiuseppe AprileMonica RamelloRaffaele ConcaRoberto PetrioliGabriele PerroneAnna IanzaEnrico MiniPublished in: Future oncology (London, England) (2023)
Background: Pancreatic cancer (PC) is one of the most lethal malignancies worldwide. This study evaluated the prognostic role of serum alanine phosphatase (ALP) and gamma-glutamyl-transferase (GGT) in metastatic PC patients. Materials & methods: 153 patients with metastatic PC receiving first-line treatment with nab-paclitaxel/gemcitabine were retrospectively enrolled in a multicenter study and stratified according to ALP (≤ or >260 U/l) and GGT (≤ or >45.5 U/l) levels. Results: Improved overall survival was recorded in patients with GGT levels ≤45.5 U/l (p < 0.05). In patients with liver metastasis, overall survival was significantly lower in patients with high ALP (p = 0.01) and GGT (p = 0.02). Conclusion: High levels of ALP and GGT were related to a poor prognosis in PC patients with liver metastasis receiving nab-paclitaxel/gemcitabine.
Keyphrases
- poor prognosis
- long non coding rna
- end stage renal disease
- squamous cell carcinoma
- ejection fraction
- newly diagnosed
- small cell lung cancer
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- advanced non small cell lung cancer
- patient reported outcomes
- free survival
- radiation therapy
- chemotherapy induced
- patient reported